ArriVent BioPharma, Inc. AVBP Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s investing cash flow?
- ArriVent BioPharma, Inc. (AVBP) reported investing cash flow of $3.58M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s investing cash flow changed year-over-year?
- ArriVent BioPharma, Inc.'s investing cash flow decreased by 90.3% year-over-year, from $36.82M to $3.58M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.